Antibiotic exposure at the site of infection: principles and assessment of tissue penetration

References

• Jager NGL, van Hest RM, Lipman J, et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol. 2016;9:961–979.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically Ill patients? Clin Infect Dis. 2014;58:1072–1083.
   PubMed Web of Science ®Google Scholar
• Kashuba ADM, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–629.
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942.
   PubMed Web of Science ®Google Scholar
• Barza M, Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother. 1985;15(Suppl A):59–75.
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J. Molecular biology of the cell. New York (NY): Garland Science; 2002.
   Google Scholar
• Hoffstedt B, Walder M. Influence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue fluid in humans. Antimicrob Agents Chemother. 1981;20:783–786.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clin Microbiol Infect. 2000;6:46–49.
   PubMed Web of Science ®Google Scholar
• Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother. 1993;31:1–16.
   PubMed Web of Science ®Google Scholar
• Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis. 1991;22:23–33.
   Google Scholar
• Landersdorfer JB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone. Clin Pharmacokinet. 2009;48:89–124.
   PubMed Web of Science ®Google Scholar
• Miller DS, Bauer B, Hartz AMS. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196–209.
   PubMed Web of Science ®Google Scholar
• Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858–883.
   PubMed Web of Science ®Google Scholar
• Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9:5–9.
   PubMed Web of Science ®Google Scholar
• Spector R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem. 2010;112:13–23.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonaryepithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet. 2011;50:689–704.
   PubMed Web of Science ®Google Scholar
• Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52:24–36.
   PubMed Web of Science ®Google Scholar
• Kumta N, Roberts JA, Lipman J, et al. antibiotic distribution into cerebrospinal fluid: can dosing safely account for drug and disease factors in the treatment of ventriculostomy-associated infections? Clin Pharmacokinet. 2018;57:439–454.
   PubMed Web of Science ®Google Scholar
• Quagliarello VJ, Ma A, Stukenbrok H, et al. Ultrastructural localization of albumin transport across the cerebral microvasculature during experimental meningitis in the rat. J Exp Med. 1991;174:657–672.
   PubMed Web of Science ®Google Scholar
• Scheld WM, Dacey RG, Winn HR, et al. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J Clin Invest. 1980;66:243–253.
   PubMed Web of Science ®Google Scholar
• von Wedel-Parlow M, Wölte P, Galla H-J. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem. 2009;111:111–118.
   PubMed Web of Science ®Google Scholar
• Thea D, Barza M. Use of antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am. 1989;3:553–570.
   PubMedGoogle Scholar
• Fong IW, Ledbetter WH, Vandenbroucke AC, et al. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother. 1986;29:405–408.
   PubMed Web of Science ®Google Scholar
• Borodin IN. Benzylpenicillin levels in the serum and bone tissue of the lower jaw in patients with chronic traumatic osteomyelitis after intraosseous and intramuscular administration. Antibiot Chemoterapy. 1988;33:694–696.
   Google Scholar
• Wilson KJ, Mader JT. Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis. Antimicrob Agents Chemother. 1984;25:140–141.
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385–391.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Schmidtko A, Bräutigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther. 2002;71:325–333.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med. 2009;37:926–933.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61:235–237.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services - Food and Drug Administration. Bioanalytical Method Validation. FDA; Rockville, USA. 2018.
   Google Scholar
• European Medicines Agency. Guideline on bioanalytical method validation. EMA; London, UK. 2011.
   Google Scholar
• Azeredo FJ, Dalla Costa T, Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet. 2014;53:205–212.
   PubMed Web of Science ®Google Scholar
• Brunner M, Derendorf H. Clinical microdialysis: current applications and potential use in drug development. TrAC - Trends Anal Chem. 2006;25:674–680.
   Web of Science ®Google Scholar
• Barbour A, Schmidt S, Sabarinath SN, et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother. 2009;53:2773–2776.
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother. 2006;58:632–636.
   PubMed Web of Science ®Google Scholar
• Burian B, Zeitlinger M, Donath O, et al. Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers. Antimicrob Agents Chemother. 2012;56:532–535.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Hope WW, Boyd SE. Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol. 2017;36:114–123.
   PubMed Web of Science ®Google Scholar
• Kozak AJ, Gerding DN, Peterson LR, et al. Gentamicin intravenous infusion rate: effect on interstitial fluid concentration. Antimicrob Agents Chemother. 1977;12:606–608.
   PubMed Web of Science ®Google Scholar
• Thys JP, Klastersky J, Mombelli G. Peak or sustained antibiotic serum levels for optimal tissue penetration. J Antimicrob Chemother. 1981;8(Suppl C):29–36.
   PubMed Web of Science ®Google Scholar
• Peterson LR, Gerding DN, Fasching CE. Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion. J Antimicrob Chemother. 1981;7:71–79.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Van Etta LL, Peterson LR. Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime. Antimicrob Agents Chemother. 1982;22:844–847.
   PubMed Web of Science ®Google Scholar
• Cronberg S. A simple mathematical model for diffusion of drug into an infection site. Scand J Infect Dis Suppl. 1978;10:100–104.
   PubMedGoogle Scholar
• Sauermann R, Burian B, Burian A, et al. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. J Antimicrob Chemother. 2013;68:895–899.
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother. 2006;50:1372–1375.
   PubMed Web of Science ®Google Scholar
• Sweetman SC. Martindale: the complete drug reference. Pharmaceutical Press; London, UK. 2009.
   Google Scholar
• Pea F. Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29:153–159.
   PubMed Web of Science ®Google Scholar
• Pfizer. Vancomycin - summary of product characteristics. Pfizer Inc.; New York, USA. 2017.
   Google Scholar
• Sanofi. Teicoplanin - summary of product characteristics. Sanofi; Paris, France. 2014.
   Google Scholar
• Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother. 1995;36:43–56.
   PubMed Web of Science ®Google Scholar
• Teva. Colistimethate sodium - summary of product characteristics. Teva Pharmaceutical Industries Ltd; Petah Tikva, Israel. 2018.
   Google Scholar
• Merck, Sharp & Dhome. Daptomycin - summary of product characteristics. Merck & Co, Inc; Kenilworth, USA. 2018.
   Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605–4610.
   PubMed Web of Science ®Google Scholar
• Clewe O, Goutelle S, Conte JE, et al. A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells–using rifampicin as an example. Eur J Clin Pharmacol. 2015;71:313–319.
   PubMed Web of Science ®Google Scholar
• Goutelle S, Bourguignon L, Maire PH, et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53:2974–2981.
   PubMed Web of Science ®Google Scholar
• Stein GE, Throckmorton JK, Scharmen AE, et al. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother. 2013;68:2852–2858.
   PubMed Web of Science ®Google Scholar
• Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019;81:128–136.
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet. 1989;16:25–31.
   PubMed Web of Science ®Google Scholar
• Wouthuyzen-Bakker M, Löwik CAM, Knobben BAS, et al. Use of gentamicin-impregnated beads or sponges in the treatment of early acute periprosthetic joint infection: a propensity score analysis. J Antimicrob Chemother. 2018;73:3454–3459.
   PubMed Web of Science ®Google Scholar
• Heffernan AJ, Sime FB, Lipman J, et al. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. Int J Antimicrob Agents. 2019;53:234–245.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Drusano GL, Butterfield JM, et al. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother. 2011;55:5507–5511.
   PubMed Web of Science ®Google Scholar
• Beach JE, Perrott J, Turgeon RD, et al. Penetration of vancomycin into the cerebrospinal fluid: a systematic review. Clin Pharmacokinet. 2017;56:1479–1490.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Sorgel F, Melnick D, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011;55:1606–1610.
   PubMed Web of Science ®Google Scholar
• Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015;70:207–216.
   PubMed Web of Science ®Google Scholar
• Piva S, Di Paolo A, Galeotti L, et al. Daptomycin plasma and CSF levels in patients with healthcare-associated meningitis. Neurocrit Care. 2019 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ziglam HM, Baldwin DR, Daniels I, et al. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2002;50:1011–1015.
   PubMed Web of Science ®Google Scholar
• Castellino S. MALDI imaging MS analysis of drug distribution in tissue: the right time!(?). Bioanalysis. 2012;4:2549–2551.
   PubMed Web of Science ®Google Scholar
• Leegsma-Vogt G, Janle E, Ash SR, et al. Utilization of in vivo ultrafiltration in biomedical research and clinical applications. Life Sci. 2003;73:2005–2018.
   PubMed Web of Science ®Google Scholar